(1S,4S)-tert-butyl 5-(5-bromopyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate | 274681-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (1S,4S)-tert-butyl 5-(5-bromopyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• 英文别名: 1,1-dimethylethyl (1S)-2-(5-bromo-pyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-5-carboxylate；tert-butyl (1S,4S)-5-(5-bromo-3-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate；tert-butyl (1S,4S)-5-(5-bromopyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• CAS: 274681-08-2
• 化学式: C₁₅H₂₀BrN₃O₂
• 分子量: 354.247
• InChiKey: ORLLKFPKPYPAHR-STQMWFEESA-N

物化性质

• 沸点：
  448.6±45.0 °C(Predicted)
• 密度：
  1.427±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S,4S)-tert-butyl 5-(5-bromopyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 生成 (1S,4S)-2-(5-bromo-3-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane 4-methylbenzenesulfonate
  参考文献：
  名称：

  Diazabicyclic CNS active agents

  摘要：

  公式I：1的化合物或其药用盐对于控制哺乳动物的突触传递是有用的。

  公开号：

  US20030225268A1
• 作为产物：
  描述：

  3,5-二溴吡啶 、 (1S,4S)-2-Boc-2,5-二氮双环[2.2.1]庚烷 生成 (1S,4S)-tert-butyl 5-(5-bromopyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
  参考文献：
  名称：

  Diazabicyclic CNS active agents

  摘要：

  化合物I的公式或其药学上可接受的盐，对于控制哺乳动物的突触传递是有用的。

  公开号：

  US07265115B2

文献信息

• Compounds as syk kinase inhibitors
  申请人：Almirall, S.A.

  公开号：EP2489663A1

  公开（公告）日：2012-08-22

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

  本发明涉及一种化合物（I）的公式，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过抑制Syk激酶而得到改善。
• 2,5,-diazabicyclo[2.2.1]heptane derivatives, their preparation and therapeutic uses
  申请人：Sanofi-Synthelabo

  公开号：US06635645B1

  公开（公告）日：2003-10-21

  The invention relates to 2,5-diazabicyclo[2.2.1]heptane derivatives, to pharmaceutical compositions containing them, and to methods for the treatment or prevention of disorders associated with a dysfunction of the nicotinic receptors utilizing them.

  这项发明涉及2,5-二氮杂双环[2.2.1]庚烷衍生物，含有它们的药物组合物，以及利用它们治疗或预防与尼古丁受体功能障碍相关的疾病的方法。
• Pharmaceutical compositions and methods for use
  申请人：——

  公开号：US20020013309A1

  公开（公告）日：2002-01-31

  The present invention relates to diazabicyclic compounds, preferably to N-aryl diazabicyclic compounds. Of particular interest are 2-pyridyl diazabicyclic compounds, such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. Other exemplary compounds of the present invention include: (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1 ]heptane, (1S,4S)-2-(5-(3,4-dimethoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1 ]heptane, and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. The present invention also relates to prodrug derivatives of the compounds of the present invention.

  本发明涉及二氮杂双环化合物，优选为N-芳基二氮杂双环化合物。特别感兴趣的是2-吡啶基二氮杂双环化合物，例如(1S,4S)-2-(5-(3-甲氧基苯氧基)-3-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷。本发明的其他示例化合物包括：(1S,4S)-2-(5-(4-甲氧基苯氧基)-3-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷，(1S,4S)-2-(5-(3,4-二甲氧基苯氧基)-3-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷，(1S,4S)-2-(5-(4-氟苯氧基)-3-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷和(1S,4S)-2-(5-苯甲酰基-3-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷。本发明还涉及本发明化合物的前药衍生物。
• Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
  申请人：ABBOTT LABORATORIES

  公开号：EP1359152A2

  公开（公告）日：2003-11-05

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

  式(I)化合物或其药学上可接受的盐 其中 V 选自由共价键和 CH2 组成的组； W 选自由共价键、CH2 和 CH2CH2 组成的组； X 选自由共价键和 CH2 组成的组； Y 选自由共价键、CH2 和 CH2CH2 组成的组； Z 选自 CH2 和 CH2CH2 及 CH2CH2CH2 组成的组； L1 选自由共价键和 (CH2)n 组成的组； n 为 1-5； R1 选自由(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)、(j)、(k)和(l)组成的组； R2 选自氢、烷氧羰基、烷基、氨基烷基、氨基羰基烷基、苄氧羰基、氰基烷基、二氢-3-吡啶基羰基、羟基、羟基烷基、苯氧羰基和-NH2 所组成的组； 可用于控制哺乳动物的突触传递。
• DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：ABBOTT LABORATORIES

  公开号：EP1147112B1

  公开（公告）日：2003-10-29